Regulatory Approvals

Recon: FDA clears Roche, Lilly Alzheimer’s blood tests; Regenxbio gene therapy trial halted by FDA again

By

Regulatory Approvals — Recon: FDA clears Roche, Lilly Alzheimer’s blood tests; Regenxbio gene therapy trial halted by FDA again  RAPS

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. August 24, 2026.

By

Related Post

Regulatory Approvals

FDA approves new blood test for Alzheimer’s disease

Regulatory Approvals

FDA approves a new blood test to detect signs of Alzheimer’s

Regulatory Approvals

FDA Clears Roche’s Single-Biomarker Elecsys pTau217 Blood Test for Alzheimer Disease

Financial News For All

Labor

Columbia postdoctoral workers vote to authorize strike

Labor

Journalists at Daily Herald Organize to Form Union Following Recent Layoffs

Regulatory Approvals

FDA approves new Alzheimer’s blood test from Roche, Eli Lilly

Regulatory Approvals

Recon: FDA clears Roche, Lilly Alzheimer’s blood tests; Regenxbio gene therapy trial halted by FDA again